尽管生存率有所提高，但转移性去势抵抗性前列腺癌（mCRPC）仍然是一个重大的临床挑战。虽然紫杉烷类、新型激素药物、放射性药物和 PARP 抑制剂提供了有价值的治疗选择，但本综述探讨了铂化疗（卡铂、顺铂和奥沙利铂）作为替代选择的潜力。现有研究表明，针对 mCRPC 的铂类疗法取得了令人鼓舞的初步结果，显示 PSA 缓解率 (7.7-95%) 和总生存期改善 (8-26.6 个月)。然而，化疗相关的血细胞减少是一种常见的副作用。进一步的研究正在进行中，以评估铂方案对特定 mCRPC 组织病理学变异的疗效，特别是已经推荐卡铂和卡巴他赛组合的侵袭性亚型。铂类疗法独特的 DNA 靶向作用为 DNA 修复缺陷 (dDDR) 患者，尤其是 BRCA 突变患者带来希望。这种潜力得到了临床前和正在进行的临床研究的支持。鉴于免疫疗法在 mCRPC 中取得的成功有限，研究人员正在探索铂类疗法增强其疗效的潜力。此外，试验正在研究铂类疗法与免疫疗法和 PARP 抑制剂相结合的协同作用。进一步探索铂类疗法在特定 mCRPC 亚群（尤其是 dDDR 亚群）中的有效性，对于优化其未来使用至关重要。总之，本次综述强调了铂类化疗作为 mCRPC 有价值的治疗选择的巨大潜力。虽然目前的证据令人鼓舞，但持续的研究对于进一步优化其疗效、确定与其他疗法的最佳组合以及更好地了解其对特定 mCRPC 亚群的影响至关重要。版权所有 © 2024 Elsevier Ltd. 保留所有权利。

Despite improvements in survival, metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge. While taxanes, new hormonal agents, radiopharmaceuticals, and PARP inhibitors offer valuable treatment options, this review explores the potential of platinum chemotherapies (carboplatin, cisplatin, and oxaliplatin) as alternative choices. Existing research demonstrates promising preliminary results for platinum-based therapies in mCRPC showing PSA response rates (7.7-95 %) and improved overall survival (8-26.6 months). However, chemotherapy-related cytopenias are a frequent side effect. Further research is underway to evaluate the efficacy of platinum regimens against specific mCRPC histopathological variants, particularly aggressive subtypes where the carboplatin and cabazitaxel combination is already recommended. The unique DNA-targeting action of platinum therapy holds promise for patients with deficient DNA repair (dDDR), especially those with BRCA mutations. This potential is supported by both preclinical and ongoing clinical research. Given the limited success of immunotherapy in mCRPC, researchers are exploring the potential for platinum therapies to enhance its efficacy. Additionally, trials are investigating the synergy of combining platinum therapy with both immunotherapy and PARP inhibitors. Further exploration into the effectiveness of platinum therapies in specific mCRPC subpopulations, particularly those with dDDR, is crucial for optimizing their future use. In conclusion, this review highlights the promising potential of platinum-based chemotherapy as a valuable treatment option for mCRPC. While current evidence is encouraging, ongoing research is essential to further optimize its efficacy, identify optimal combinations with other therapies, and better understand its impact on specific mCRPC subpopulations.Copyright © 2024 Elsevier Ltd. All rights reserved.